2021年 · 第41卷第01期

Tumor treatment includes surgery, radiotherapy and chemotherapy. According to the World Health Organization (WHO), about 70% of cancer patients need radiation therapy. According to the latest statistics of the American Cancer Society, the tumor cure rate has reached 67%, of which surgery and radiotherapy each account for 30%. The role of radiotherapy is increasingly prominent^[1]。 Radiation therapy includes external irradiation and internal irradiation. Internal irradiation is also called brachytherapy (BT). Commonly used brachytherapy techniques in clinic include high-dose-rate brachytherapy (HDR-BT) and low-dose-rate brachytherapy (LDR-BT). LDR-BT is also called radioactive seed implantation therapy (abbreviated as seed implantation). In recent years, seed implantation therapy technology has developed rapidly. Its principle is to directly implant radioactive particles into the tumor site through puncture guidance technology, and effectively kill tumor cells through its continuous release of low-energy gamma rays, so as to achieve the purpose of treating tumors. Brachytherapy has the advantages of high local dose and small damage to normal tissues, and has a curative effect comparable to surgery and external irradiation in the treatment of early prostate cancer. It truly realizes the cure of tumors while preserving organ functions to the maximum extent, and opens a new era of minimally invasive tumors and organ preservation. This topic focuses on the latest technological progress and application of radioactive particle implantation in the treatment of tumors, and summarizes the systematic research, hoping to give clinicians support and technical guidance.